New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Hea... (that the safety profile forCRESTOR is in...)

New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure

Date:11/5/2007

that the safety profile for CRESTOR is in line with other marketed statins.

About CRESTOR

CRESTOR is a once-daily prescription statin medication indicated for use as an adjunct to diet in the treatment of various lipid disorders including primary hypercholesterolemia, mixed dyslipidemia and isolated hypertriglyceridemia, available in a 5-, 10-, 20-, and 40-mg dose. CRESTOR has not been determined to prevent heart disease, heart attacks, or strokes. For patients with hypercholesterolemia and mixed dyslipidemia, the usual recommended starting dose of CRESTOR is 10 mg. However, initiation of therapy with 5 mg once daily should be considered for patients requiring less aggressive LDL-C reductions or who have predisposing factors for myopathy, and for special populations such as patients taking cyclosporine, Asian patients, and patients with severe renal insufficiency. For patients with marked hypercholesterolemia (LDL-C >190 mg/dL) and aggressive lipid targets, a 20-mg starting dose may be considered. AstraZeneca licensed worldwide rights to CRESTOR from the Japanese pharmaceutical company Shionogi & Co., Ltd. For more complete prescribing information, please visit: http://www.crestor.com.

Important Safety Information

CRESTOR is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases, in women who are pregnant or may become pregnant, and in nursing mothers. It is recommended that liver function tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with CRESTOR and with other drugs in this class. The 40-mg dose of CRESTOR is reserved only for those patients who have not achieved their LDL-C goal utilizing the 20-mg dose of CRESTOR once d
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. AAHC Examines Nations Clinical Trials Infrastructure
2. Endoscopy Identified as Safe and Effective Method in Treating Common Complication of Gastric Bypass Surgery
3. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
4. DNA Test Predicts Harmful Effects of Cancer Drug
5. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
6. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
7. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
8. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
9. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects

Post Your Comments:

(Date:12/15/2009)... OBP Medical Inc. declares victory in the battle ... hospitals. ,, Doctors at Newton-Wellesley Hospital in Newton, ... Medical,s Under Johnnies(TM) on patients, comfort and satisfaction ... is comparing patients, perception of comfort, privacy and ... Johnnies(TM) against the traditional hospital gown and socks. ...

(Date:12/14/2009)... Dec. 14 Embarrassing and sometimes uncomfortable colonoscopies ... National researchers are taking note of a new screening ... process. The Knoxville-based company, EDP Biotech Corporation ... ColoMarker, an affordable medical device doctors can use to ... "When you consider that 30% of colon cancer ...

(Date:12/14/2009)... 14 The board of directors of Eli ... declared a dividend for the first quarter of 2010 ... ,, The dividend is payable March 10, 2010 ... on ,, February 12, 2010. ,, Lilly, a ... pharmaceutical products by applying the latest research from its ...

[0] Under Johnnies(TM) Proven To Increase Patient Satisfaction by OBP Medical Inc.[0] EDP Biotech Takes Next Step in the Development of ColoMarker [0] Lilly Declares First-Quarter 2010 Dividend

... Vical Incorporated (Nasdaq:,VICL) today reported financial results for ... quarter of 2007 were $3.1 million, compared with,revenues of ... net loss for,the second quarter of 2007 was $8.2 ... of $3.2 million, or $0.11 per share, for the ...

... Progression Rates Are the ... Resources, WALTHAM, Mass., Aug. 7 Decision ... advisory firms focusing on pharmaceutical,and healthcare issues, finds ... Sutent as the clinical gold standard for,the treatment ...

Other Medicine Technology:Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 2 Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 3 Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 4 Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 5 Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs 6 Wyeth's Torisel and Roche/Genentech's Avastin Will Challenge Pfizer's Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma 2

Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs Wyeth's Torisel and Roche/Genentech's Avastin Will Challenge Pfizer's Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma

(Date:12/14/2009)... and more… , ... Santa Barbara, ... with scientists at University of Michigan, have developed synthetic particles ... red blood cells, including softness, flexibility, and the ability to ... of natural red blood cells is to carry oxygen, and ...

(Date:12/14/2009)... -- Americold Realty Trust ("Americold") announced today that it ... the U.S. Securities and Exchange Commission (the "SEC") relating ... shares. The number of shares to be offered and ... been determined. The common shares to be sold in ... ,, The joint book-running managers of the offering ...

(Date:12/14/2009)... Organization for Rare Disorders (NORD) today called upon Congress ... health insurance caps. In a full-page ad in ... Capitol Hill, NORD said the current Senate health reform ... for most Americans, contrary to what many people believe. ... the promises made by President Obama and Congress to ...

(Date:12/14/2009)... replaced tube watching , , MONDAY, Dec. 14 (HealthDay News) ... of television a week until he enrolled in a ... in half. , During his enforced period of deprivation, ... necessarily through strenuous exercise, although he did find his ... was spent reading and working on the computer, said ...

(Date:12/14/2009)... Ohio, Dec. 14 Skilled nursing facilities (SNFs) ... services in order to deal with a 92 percent ... fee) from $6.25 to $12.01 per bed per day, ... the average facility will pay an additional $17,520 to ... a total tax of $438,365 yearly. ,, Nearly 96 ...

Breaking Medicine News(10 mins):Health News:Synthetic Red Blood Cells Developed 2 Health News:Synthetic Red Blood Cells Developed 3 Health News:Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering 2 Health News:NORD Calls for Immediate End to Lifetime Insurance Caps 2 Health News:Cutting TV Time Burns More Calories 2 Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 2 Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 3

[0] Synthetic Red Blood Cells Developed [0] Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering [0] NORD Calls for Immediate End to Lifetime Insurance Caps [0] Cutting TV Time Burns More Calories [1] Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts

... Journal of Occupational and Environmental Medicine, Investigates Relationship of Co-payments, ... ... Utilization, PHILADELPHIA, May 12 High prescription drug,co-payments are ... to a new study published this month in the,Journal of ...

... it has long been known that embryonic stem cells ... tissue-specific cells, the exact mechanism as to how this ... the Hebrew University of Jerusalem and elsewhere have succeeded ... as to whether the stem cells achieve their development ...

... think before they drink as part of a research project ... of health psychologists at The University of Nottingham plan to ... health effects of binge drinking and asking employees for a ... single session could change peoples binge drinking behaviour in the ...

... ULURU Inc. (Amex: ULU ),today reported financial results ... the quarter ended March 31, 2008, the net loss ... compared to a net,loss of $847,000, or $0.01 per ... 2008 net loss was impacted by non-cash expenses of,$497,000, ...

... mutated gene has been discovered as the key behind ... new research at Adelaides Womens & Childrens Hospital and ... published today in Nature Genetics, shows that although men ... The research has been led by Dr Leanne Dibbens ...

... look more attractive. Fish diet to avoid being beaten ... eaten as a result. , That is the fascinating conclusion ... the ARC Centre of Excellence for Coral Reef Studies and ... , The same team who recently revealed fish use the ...

Other Medicine News:Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 2 Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 3 Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 4 Health News:New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health 5 Health News:How embryonic stem cells develop into tissue-specific cells demonstrated 2 Health News:Think before you drink, says university research 2 Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 2 Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 3 Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 4 Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 5 Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 6 Health News:Mutant gene causes epilepsy, intellectual disability in women 2 Health News:Fish diet to avoid fights 2

New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health How embryonic stem cells develop into tissue-specific cells demonstrated Think before you drink, says university research ULURU Inc. Reports First Quarter 2008 Financial Results Mutant gene causes epilepsy, intellectual disability in women Fish diet to avoid fights

Flat tip, bare fiber, no cooling, polished SMA 905, 3 meters long. Sold in boxes of five. Each part is individually packaged in sterile Tyvek bags....

... unique lateral fiber possessing a ... rotated to any one of ... fibers in one. The fiber ... and coagulation and back to ...

... Ultrafin™ Stirrup is the latest ... stirrup features a roomier boot ... up to an 800 pound ... to position heavy legs more ...

... assist stirrups are designed to travel a full ... They lock tight wherever you release the rotating ... are done at the handle with no need ... socket. The rotation of system was designed to ...

Medicine Products:

Megabeam Non-Contact Fibers for Holmium Lasers QuadraLase™Ultrafin™ Stirrup Lift Assist Stirrup System

New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Hea...(that the safety profile forCRESTOR is in...),Health